These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 32865607)
21. Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience. Alahmadi M; Masih-Khan E; Atenafu EG; Chen C; Kukreti V; Tiedemann R; Trudel S; Reece DE Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e195-e203. PubMed ID: 30723035 [TBL] [Abstract][Full Text] [Related]
22. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. San-Miguel JF; Echeveste Gutierrez MA; Špicka I; Mateos MV; Song K; Craig MD; Bladé J; Hájek R; Chen C; Di Bacco A; Estevam J; Gupta N; Byrne C; Lu V; van de Velde H; Lonial S Haematologica; 2018 Sep; 103(9):1518-1526. PubMed ID: 29954932 [TBL] [Abstract][Full Text] [Related]
23. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945 [TBL] [Abstract][Full Text] [Related]
25. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Kalff A; Khong T; Mithraprabhu S; Bergin K; Reynolds J; Bowen KM; Thakurta A; Guzman R; Wang M; Couto S; Ren Y; Spencer A Leuk Lymphoma; 2019 Sep; 60(9):2143-2151. PubMed ID: 31184224 [TBL] [Abstract][Full Text] [Related]
26. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Rajkumar SV; Jacobus S; Callander NS; Fonseca R; Vesole DH; Williams ME; Abonour R; Siegel DS; Katz M; Greipp PR; Lancet Oncol; 2010 Jan; 11(1):29-37. PubMed ID: 19853510 [TBL] [Abstract][Full Text] [Related]
27. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405 [TBL] [Abstract][Full Text] [Related]
28. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT; J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703 [TBL] [Abstract][Full Text] [Related]
29. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Wang M; Martin T; Bensinger W; Alsina M; Siegel DS; Kavalerchik E; Huang M; Orlowski RZ; Niesvizky R Blood; 2013 Oct; 122(18):3122-8. PubMed ID: 24014245 [TBL] [Abstract][Full Text] [Related]
30. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411 [TBL] [Abstract][Full Text] [Related]
31. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Goldschmidt H; Mai EK; Dürig J; Scheid C; Weisel KC; Kunz C; Bertsch U; Hielscher T; Merz M; Munder M; Lindemann HW; Hügle-Dörr B; Tichy D; Giesen N; Hose D; Seckinger A; Huhn S; Luntz S; Jauch A; Elmaagacli A; Rabold B; Fuhrmann S; Brossart P; Goerner M; Bernhard H; Hoffmann M; Hillengass J; Raab MS; Blau IW; Hänel M; Salwender HJ; Leukemia; 2020 Jul; 34(7):1853-1865. PubMed ID: 32034285 [TBL] [Abstract][Full Text] [Related]
32. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers. Hose D; Schreder M; Hefner J; Bittrich M; Danhof S; Strifler S; Krauth MT; Schoder R; Gisslinger B; Einsele H; Gisslinger H; Knop S J Cancer Res Clin Oncol; 2021 Jan; 147(1):205-212. PubMed ID: 32683487 [TBL] [Abstract][Full Text] [Related]